Microglia activation represents the innate immune response of the brain, playing a dual role in neurodegeneration—protective clearance of pathogens and debris versus chronic neuroinflammation that drives disease progression[1]. These resident macrophages constitute 10-15% of brain cells and are critical in Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders[2].
Microglia are unique immune cells of the central nervous system (CNS) that originate from embryonic yolk sac progenitors and self-renew locally throughout life[3]. Unlike peripheral macrophages, microglia maintain their population through self-proliferation rather than continuous recruitment from bone marrow-derived monocytes[4]. This self-renewal capacity is mediated by the colony-stimulating factor 1 receptor (CSF1R) signaling pathway, which has become a therapeutic target for modulating microglial abundance in disease states[5].
The concept of microglial polarization has evolved significantly over the past decade. Initially described as a binary M1/M2 classification, current understanding recognizes microglia exist on a spectrum of activation states influenced by the local microenvironment[6]. This spectrum includes surveillant (homeostatic), disease-associated microglia (DAM), and various intermediate phenotypes that can transition between states depending on pathological cues[7].
Microglia arise from primitive macrophages in the embryonic yolk sac during early development (embryonic day 7-8 in mice)[8]. This distinct ontogeny explains their unique transcriptional signature compared to peripheral myeloid cells[9]. The transcription factor PU.1 (encoded by SPI1) is essential for microglial development, and conditional knockout results in complete absence of microglia in the adult brain[10].
Key developmental transcription factors include:
The embryonic origin of microglia was definitively established through fate-mapping studies using the Cx3cr1CreER system, which demonstrated that adult microglia derive exclusively from yolk sac progenitors that colonize the brain rudiment before the onset of definitive hematopoiesis[11].
In the healthy adult brain, microglia maintain homeostasis through continuous surveillance of their territory[12]. Each microglia extends highly motile processes that scan the surrounding parenchyma every few hours, enabling rapid detection of pathological changes[13]. This surveillance function is energy-intensive and requires intact mitochondrial metabolism[14].
The adult microglial population turns over slowly, with an estimated half-life of several years in humans[15]. However, this turnover can be dramatically accelerated in disease states, where microglial proliferation becomes a major source of new microglia at lesion sites[16].
Microglia exhibit remarkable heterogeneity across different brain regions. Transcriptomic studies have identified region-specific microglial signatures, with the hippocampus and substantia nigra showing distinct gene expression patterns[17]. This heterogeneity likely reflects adaptations to local neuronal populations, synaptic activity, and microenvironmental cues.
| Brain Region | Key Features | Density (cells/mm³) |
|---|---|---|
| Cortex | Surveillance-dominant | 5,000-10,000 |
| Hippocampus | High plasticity markers | 8,000-12,000 |
| Substantia nigra | High activation markers | 10,000-15,000 |
| Cerebellum | Unique transcriptional profile | 3,000-6,000 |
| White matter | Lower density | 2,000-5,000 |
Resting microglia in the healthy brain maintain a characteristic phenotype:
The homeostatic microglial transcriptome is defined by a set of "microglial signature genes" including CX3CR1, P2RY12, P2RY13, TMEM119, HEXB, and CSF1R[18]. These genes are downregulated upon activation and serve as markers of the surveillant state.
Key homeostatic functions include:
The transition from surveillance to activated states is tightly regulated by pattern recognition receptors (PRRs) that detect damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs)[22].
Classical activation driven by:
Key markers: CD16, CD32, CD86, iNOS, MHC-II, CCR7, FCGR1A
Secreted factors:
The classical activation cascade involves recognition of ligands by TLR4, recruitment of adaptor proteins MyD88 and TRIF, activation of NF-κB and IRF3 transcription factors, and subsequent transcription of inflammatory genes[23]. IFN-γ synergizes with TLR signaling through STAT1 activation, amplifying the inflammatory response.
Alternative activation driven by:
Key markers: CD206 (mannose receptor), Arg1, YM1, Fizz1, IL-10, TGF-β, CCL17, CCL22
Secreted factors:
IL-4 signaling activates STAT6, which drives expression of arginase-1 (Arg1), YM1, and Fizz1[24]. These genes encode proteins involved in tissue repair and anti-inflammatory functions. The Arg1 enzyme competes with iNOS for L-arginine substrate, thereby reducing NO production and promoting polyamine synthesis for cell proliferation and tissue remodeling.
A specialized microglial phenotype identified in Alzheimer's disease represents a distinct activation state[25]:
Key genes upregulated in DAM: APOE, TREM2, CTSD (cathepsin D), LPL (lipoprotein lipase), ITGAX (CD11C), CLEC7A[26]
The transition from homeostatic microglia to DAM requires functional TREM2, and loss-of-function TREM2 variants block the DAM response, leading to reduced amyloid plaque compaction and altered plaque morphology[27].
Recent single-cell studies have revealed additional microglial states:
TREM2 variants significantly alter microglial function and modify Alzheimer's disease risk[32]:
| Variant | Effect on Function | Disease Association | Frequency |
|---|---|---|---|
| R47H | Loss of lipid binding, reduced phagocytosis | ~3x AD risk | 0.3-0.5% |
| R62H | Reduced ligand recognition | ~2x AD risk | 0.5-0.7% |
| R33X | Truncated protein, no signaling | Nasu-Hakola disease | Rare |
| D87N | Impaired signaling | AD risk variant | 0.1% |
| T96K | Reduced function | AD risk variant | Rare |
These loss-of-function variants demonstrate that reduced microglial phagocytic capacity increases AD risk, highlighting the protective role of microglia in clearing amyloid deposits[33].
Microglia in AD exhibit both protective and pathogenic roles depending on disease stage[34]:
| Phase | TREM2 Status | Microglial Function | Therapeutic Implication |
|---|---|---|---|
| Pre-clinical | Normal | Surveillance, Aβ clearance | Support TREM2 function |
| Early | Risk variant (R47H) | Reduced amyloid clearance | TREM2 agonists |
| Mid | TREM2 upregulation | Plaque-associated clustering | May be protective |
| Late | TREM2 dysfunction | Chronic inflammation | Anti-inflammatory |
Key interactions:
The microglial landscape in AD has been extensively characterized through single-cell RNA sequencing, revealing disease-specific transcriptional programs that differ from aging microglia[35]. Apoe-expressing microglia cluster near amyloid plaques and display enhanced antigen presentation and inflammatory gene expression[36].
Amyloid clearance mechanisms:
Tau pathology propagation:
Complement-mediated synapse loss:
Microglial activation in PD is among the earliest pathological changes[38]:
Triggers:
Neuroinflammatory cascade:
Genetic risk factors:
Microglia in ALS demonstrate rapid activation concurrent with motor neuron loss[41]:
Microglial phenotypes in ALS:
SOD1 models:
Microglia play complex roles in demyelination and remyelination[43]:
Lesion stages:
The primary driver of pro-inflammatory gene expression:
TLR4 activation → MyD88 → IRAK4/1 → TRAF6 → IKK → IκB degradation
↓
NF-κB translocation
↓
Pro-inflammatory gene transcription
Key targets:
Intracellular sensor for DAMPs that amplifies inflammation[44]:
DAMP recognition → ASC recruitment → Pro-caspase-1 activation
↓
Pro-IL-1β + pro-IL-18 cleavage
↓
IL-1β/IL-18 release
In AD, Aβ activates NLRP3, creating a chronic inflammatory loop[45]. NLRP3 deficiency in mouse models reduces amyloid pathology and improves cognitive function[46]. The inflammasome requires two signals: priming (NF-κB-dependent) and activation (ROS, potassium efflux, lysosomal damage).
Myeloid cell receptor for lipid metabolism and phagocytosis[47]:
TREM2 signaling regulates:
DNA sensing pathway increasingly implicated in neurodegeneration[48]:
p38 MAPK and JNK pathways mediate stress responses:
Microglia undergo characteristic morphological transformations:
These morphological changes correlate with functional states and can be visualized using Iba1, TMEM119, or P2RY12 immunostaining[49]. Three-dimensional reconstruction reveals process complexity decreases with activation while soma size increases.
| Approach | Target | Agent | Status |
|---|---|---|---|
| CSF1R antagonism | Reduce microglial numbers | PLX3397 | Preclinical |
| CSF1R antagonism | Reduce microglial numbers | PLX5622 | Preclinical |
| CSF1R antagonism | Reduce microglial numbers | BLZ945 | Phase 1/2 |
| CSF1R antagonism | Reduce microglial numbers | Tiludronate | Phase 2 |
PLX5622 treatment in 5xFAD mice reduces plaque-associated microglia and improves cognitive function[50]. However, complete microglial depletion leads to neuronal damage, suggesting a balance is needed.
| Approach | Target | Agent | Status |
|---|---|---|---|
| NLRP3 inhibition | Inflammasome | MCC950 | Preclinical |
| TREM2 agonism | Phagocytosis | Anti-TREM2 antibodies | Phase 1/2 |
| CX3CR1 antagonism | Recruitment | AZD4619 | Phase 1 |
| P2X7 antagonism | ATP signaling | CE-224,535 | Phase 2 (failed) |
| CD33 antagonism | Phagocytosis inhibition | Anti-CD33 antibodies | Preclinical |
Microglial activation can be monitored through:
TSPO PET studies demonstrate increased microglial activation in AD, PD, and ALS patients, correlating with disease severity[55]. Second-generation TSPO ligands show improved specificity.
Translational research requires understanding species differences:
Aging is associated with microglial dysfunction:
Aging microglia show a distinct transcriptional signature including upregulated stress response genes, complement components, and lysosomal genes[56].
Heneka et al. Neuroinflammation in Alzheimer's disease (2015). 2015. ↩︎
Ginhoux et al. Origin and differentiation of microglia (2013). 2013. ↩︎
Ajami et al. Local self-renewal of microglia (2007). 2007. ↩︎
Elmore et al. CSF1R signaling regulates microglia (2014). 2014. ↩︎
Krasemann et al. TREM2-Deficient Microglia (2017). 2017. ↩︎
Alliot et al. Microglia derive from yolk sac (1999). 1999. ↩︎
Kierdorf et al. Microglia development (2013). 2013. ↩︎
Schulz et al. PU.1 is essential for microglia (2012). 2012. ↩︎
Ginhoux et al. Fate mapping microglia (2010). 2010. ↩︎
Davalos et al. ATP-induced chemotaxis (2005). 2005. ↩︎
Nimmerjahn et al. Resting microglia in vivo (2005). 2005. ↩︎
Kaindlstorfer et al. Microglial energy metabolism (2015). 2015. ↩︎
Réu et al. Lifespan of human microglia (2017). 2017. ↩︎
Huang et al. Microglial proliferation in disease (2018). 2018. ↩︎
Grabert et al. Regional microglia diversity (2016). 2016. ↩︎
Butovsky et al. Microglial signature (2014). 2014. ↩︎
Tremblay et al. Microglial synaptic contact (2010). 2010. ↩︎
Mazaheri et al. Apoptotic cell clearance (2014). 2014. ↩︎
Matsumoto et al. Microglial metabolic support (2021). 2021. ↩︎
Block & Hong, Microglia and neurodegeneration (2005). 2005. ↩︎
Keren-Shaul et al. DAM microglia (2017). 2017. ↩︎
Deczkowska et al. Disease-associated microglia (2020). 2020. ↩︎
Wang et al. TREM2 and plaque morphology (2016). 2016. ↩︎
Holtman et al. Aging microglia (2015). 2015. ↩︎
Zinser et al. Injury-responsive microglia (2022). 2022. ↩︎
Berg et al. Lipid-loaded microglia (2022). 2022. ↩︎
Zhou et al. Proliferative response microglia (2022). 2022. ↩︎
Guerreiro et al. TREM2 variants in AD (2013). 2013. ↩︎
Jonsson et al. TREM2 and AD risk (2013). 2013. ↩︎
Heneka et al. microglia in AD (2020). 2020. ↩︎
Mathys et al. Single-cell analysis of AD (2019). 2019. ↩︎
Krasemann et al. TREM2-APOE pathway (2017). 2017. ↩︎
Stephan et al. Complement and synapse elimination (2013). 2013. ↩︎
Block et al. Microglia and Parkinson's disease (2007). 2007. ↩︎
Moehle et al. LRRK2 and neuroinflammation (2012). 2012. ↩︎
Chahine et al. GBA and Parkinson's disease (2013). 2013. ↩︎
Appel et al. Non-cell-autonomous toxicity in ALS (2010). 2010. ↩︎
Frakes et al. Microglia in ALS progression (2014). 2014. ↩︎
Lassmann et al. Microglia in multiple sclerosis (2021). 2021. ↩︎
Heneka et al. NLRP3 inflammasome in AD (2013). 2013. ↩︎
Masters et al. Aβ activates NLRP3 (2020). 2020. ↩︎
Coll et al. NLRP3 deficiency in AD (2015). 2015. ↩︎
Painter et al. TREM2 structure and function (2015). 2015. ↩︎
Gulen et al. cGAS-STING in neurodegeneration (2020). 2020. ↩︎
Ayata et al. Microglial morphology (2018). 2018. ↩︎
Spangenberg et al. PLX5622 reduces microglia (2019). 2019. ↩︎
Gordon et al. Minocycline in ALS (2007). 2007. ↩︎
Piette et al. Masitinib in ALS (2021). 2021. ↩︎
Kreisl et al. TSPO PET in neurodegeneration (2013). 2013. ↩︎
Suarez-Fartinez et al. sTREM2 as biomarker (2018). 2018. ↩︎
Cagnin et al. In vivo microglial activation (2001). 2001. ↩︎
Streit et al. Microglia and aging (2014). 2014. ↩︎